Research Library — Page 9 | Reta Compare

402 research articles. Page 9 of 17.

Articles

• Exploring Retatrutide: Insights from Recent Advances in Obesity Pharmacotherapy
• Exploring Retatrutide: Insights from ObesityWeek 2023 on Weight-Loss Medications
• Retatrutide's Role in Treating NAFLD and MASLD: Insights from Recent Research
• Exploring the Role of Retatrutide in Diabetes and Obesity Management
• Retatrutide: A Potential New Treatment for Obesity and Type 2 Diabetes
• Exploring Retatrutide: A Triple Agonist in Obesity Management and Cardiovascular Safety
• Exploring Retatrutide: A Triple-Hormone-Receptor Agonist for Obesity Management
• Exploring the Role of Retatrutide as a Triple-Hormone-Receptor Agonist for Obesity Management
• Exploring the Role of Retatrutide as a Triple-Hormone-Receptor Agonist in Obesity Treatment
• Exploring the Role of Retatrutide in Triple Hormone Receptor Activation
• Retatrutide's Impact on Gastric Emptying: Insights from Recent Research
• Retatrutide Shows Promising Efficacy in Type 2 Diabetes Management
• Retatrutide's Efficacy in Weight Loss: Insights from a Phase 2 Trial
• Retatrutide Shows Significant Weight Loss in Triple-Hormone Combination Therapy
• Understanding Adipocyte Differentiation and Lipolytic Function in Retatrutide Research
• Exploring Retatrutide: A New Approach to Diabetes and Obesity Treatment
• Exploring the Role of Enteroendocrine Cells in Retatrutide Mechanisms
• Retatrutide: Insights from the Phase 1b Trial of LY3437943 in Type 2 Diabetes
• Exploring Retatrutide: Insights from LY3437943 as a Triple Agonist for Metabolic Health
• Evaluating Retatrutide's Impact on Cardiovascular and Kidney Health in Obesity
• Exploring the Efficacy and Safety of Retatrutide in Non-Diabetic Participants with Obesity
• Retatrutide in Preventing Major Adverse Liver Outcomes in MASLD Patients
• Evaluating Retatrutide for Chronic Low Back Pain in Obese Individuals
• Evaluating the Efficacy of Retatrutide for Weight Reduction in Obesity
• Evaluating the Efficacy of Retatrutide in Type 2 Diabetes with Obesity